Cytarabine
- Generic Name
- Cytarabine
- Brand Names
- Cytosar, Vyxeos
- Drug Type
- Small Molecule
- Chemical Formula
- C9H13N3O5
- CAS Number
- 147-94-4
- Unique Ingredient Identifier
- 04079A1RDZ
- Background
A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)
- Indication
For the treatment of acute non-lymphocytic leukemia, acute lymphocytic leukemia and blast phase of chronic myelocytic leukemia.
Cytarabine is indicated in combination with daunorubicin for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.
- Associated Conditions
- Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Acute Promyelocytic Leukemia, Meningeal leukemia, Metastatic Malignant Neoplasm to the Leptomeninges, Non-Hodgkin's Lymphoma (NHL), Treatment-Related Acute Myeloid Leukemia, Blast phase Chronic myeloid leukemia
Combination Chemotherapy Followed By Donor Bone Marrow or Umbilical Cord Blood Transplant in Treating Children With Newly Diagnosed Juvenile Myelomonocytic Leukemia
- Conditions
- Juvenile Myelomonocytic Leukemia
- Interventions
- Radiation: radiation therapyBiological: anti-thymocyte globulinProcedure: allogeneic bone marrow transplantationProcedure: double-unit umbilical cord blood transplantationProcedure: umbilical cord blood transplantationOther: laboratory biomarker analysis
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-04-11
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 100
- Registration Number
- NCT00025038
- Locations
- 🇺🇸
Children's Oncology Group, Arcadia, California, United States
Combination Chemotherapy With or Without Donor Bone Marrow Transplantation in Treating Infants With Previously Untreated Acute Lymphoblastic Leukemia
- Conditions
- Leukemia
- Interventions
- Procedure: allogeneic bone marrow transplantationRadiation: radiation therapy
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2014-02-20
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 6
- Registration Number
- NCT00022126
- Locations
- 🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸Emory University Hospital - Atlanta, Atlanta, Georgia, United States
🇺🇸Loma Linda University Medical Center, Loma Linda, California, United States
Combination Chemotx in Treating Children or Adolescents With Newly Diagnosed Stg III or Stg IV Lymphoblastic Lymphoma
- Conditions
- Lymphoma
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2019-08-06
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 393
- Registration Number
- NCT00004228
- Locations
- 🇺🇸
Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas, Dallas, Texas, United States
🇺🇸Memorial Cancer Institute at Memorial Regional Hospital, Hollywood, Florida, United States
🇺🇸MBCCOP - Medical College of Georgia Cancer Center, Augusta, Georgia, United States
Chemotherapy and Radiation Therapy Plus Bone Marrow Transplantation in Treating Patients With Aggressive Non-Hodgkin's Lymphoma
- Conditions
- Lymphoma
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-09-17
- Lead Sponsor
- Scotland and Newcastle Lymphoma Group
- Registration Number
- NCT00003815
- Locations
- 🇬🇧
Newcastle Upon Tyne Hospitals NHS Trust, Newcastle-Upon-Tyne, England, United Kingdom
Chemotherapy Followed by Donor White Blood Cells Plus Interleukin-2 in Treating Patients With Acute Myeloid or Lymphocytic Leukemia
- Conditions
- Leukemia
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2010-04-02
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Registration Number
- NCT00005802
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
Comparison of Different Combination Chemotherapy Regimens in Treating Children With Acute Lymphoblastic Leukemia
- Conditions
- Leukemia
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2016-02-23
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 3054
- Registration Number
- NCT00005945
- Locations
- 🇺🇸
Medical City Dallas Hospital, Dallas, Texas, United States
🇺🇸Ireland Cancer Center at University Hospitals of Cleveland and Case Western Reserve University, Cleveland, Ohio, United States
🇺🇸MD Anderson Cancer Center at University of Texas, Houston, Texas, United States
STI571 Plus Cytarabine in Treating Patients With Chronic Myelogenous Leukemia
- Conditions
- Blastic Phase Chronic Myelogenous LeukemiaRelapsing Chronic Myelogenous LeukemiaChronic Myelogenous Leukemia, BCR-ABL1 Positive
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-01-24
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 46
- Registration Number
- NCT00015834
- Locations
- 🇺🇸
University of California at Los Angeles (UCLA ), Los Angeles, California, United States
Chemotherapy and Rituximab With Peripheral Stem Cell Transplantation in Treating Patients With Mantle Cell Lymphoma
- Conditions
- Lymphoma
- Interventions
- Biological: filgrastimBiological: rituximabProcedure: peripheral blood stem cell transplantation
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2016-07-19
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 79
- Registration Number
- NCT00020943
- Locations
- 🇺🇸
Greenebaum Cancer Center at University of Maryland Medical Center, Baltimore, Maryland, United States
🇺🇸Cedars-Sinai Comprehensive Cancer Center at Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸Ellis Fischel Cancer Center at University of Missouri - Columbia, Columbia, Missouri, United States
S0112 Cytarabine and Daunorubicin in Treating Older Patients With Acute Myeloid Leukemia
- Conditions
- Leukemia
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2015-03-06
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 71
- Registration Number
- NCT00023777
- Locations
- 🇺🇸
MBCCOP - Gulf Coast, Mobile, Alabama, United States
🇺🇸Loyola University Medical Center, Maywood, Illinois, United States
🇺🇸Veterans Affairs Medical Center - Shreveport, Shreveport, Louisiana, United States
Chemotherapy With or Without Additional Chemotherapy and/or Radiation Therapy in Treating Children With Newly Diagnosed Hodgkin's Disease
- Conditions
- Childhood Mixed Cellularity Classical Hodgkin LymphomaStage I Childhood Hodgkin LymphomaStage IV Childhood Hodgkin LymphomaChildhood Lymphocyte-Depleted Classical Hodgkin LymphomaChildhood Nodular Lymphocyte Predominant Hodgkin LymphomaStage II Childhood Hodgkin LymphomaChildhood Nodular Sclerosis Classical Hodgkin LymphomaStage III Childhood Hodgkin Lymphoma
- Interventions
- Biological: Bleomycin SulfateBiological: FilgrastimRadiation: Involved-Field Radiation Therapy
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2017-04-12
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 1734
- Registration Number
- NCT00025259
- Locations
- 🇺🇸
UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas, United States
🇺🇸Nationwide Children's Hospital, Columbus, Ohio, United States
🇺🇸University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.